Loading clinical trials...
Loading clinical trials...
Phase I/II Study of Combination Everolimus (RAD001), and Rituximab (Rituxan), OR Everolimus, Bortezomib (Velcade, PS-341), and Rituximab in Patients With Relapsed and/or Relapsed/Refractory Waldenstrom's Macroglobulinemia
Conditions
Interventions
Everolimus
Rituximab
+1 more
Locations
1
United States
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Start Date
April 1, 2010
Primary Completion Date
December 1, 2013
Completion Date
August 1, 2014
Last Updated
April 23, 2021
NCT04274738
NCT01647971
NCT01046006
NCT00936611
NCT02363439
NCT00142116
Lead Sponsor
Dana-Farber Cancer Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions